ROCHE INVIRASE CLEARS FDA IN 97 DAYS AS FIRST APPROVED PROTEASE INHIBITOR: NEW FORMULATION IN STUDY; INTERNATIONAL CONFIMATORY TRIAL SIZE, POWER INCREASED

Hoffmann-La Roche's Invirase (saquinavir) will be the first protease inhibitor on the market following its approval 97 days after the NDA was received by FDA.